“Therapeutic inertia” is a term coined over a decade ago to describe the 90% of clinicians who failed to intensify antihypertensive therapy in patients with high blood pressure (Antrade et al. Am J Manag Care 2004l;10(7 Pt 2):481-486). The concept was first applied to multiple sclerosis treatment decision-making three years ago and has become something of a cottage industry ever since, with about a dozen papers and abstracts to date on the topic. Read More
Latest News
MS highlights from EAN 2019
July 10, 2019SPECIAL REPORT
The following summarizes some of the key data on multiple sclerosis presented at the European Academy of Neurology meeting, held 29 June – 2 July, in Oslo, Norway. Read More
HSCT vs. drug in RRMS: head-to-head study
June 19, 2019A new head-to-head trial has reported that nonmyeloablative hematopoietic stem-cell transplantation is superior to disease-modifying drugs (DMD) with respect to time to disease progression in patients with highly-active relapsing-remitting multiple sclerosis (Burt et al. JAMA 2019;321:165-174). Read More
FDA approves migraine drug for cluster headaches
June 12, 2019Galcanezumab, a calcitonin gene-related peptide (CGRP) antagonist, is the first agent to receive FDA approval for the treatment of cluster headaches. The product was accorded a priority review in March and a ruling had been expected later this year. Galcanezumab is marketed as Emgality in the U.S. and received approval for the prevention of migraine last year. It is the third CGRP-targeted monoclonal antibody for migraine prophylaxis after erenumab (Aimovig) and fremanezumab (Ajovy). Aimovig, which uniquely targets the CGRP receptor, has also received approval by Health Canada for migraine prevention. Read More